A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.
TransMedics Group, Inc. TMDX
Strong broader-coverage candidate · TransMedics Group, Inc.
On FrontierLab's discovery record since 2026-08-19 (2 days ago) — when this name first surfaced. (distinct from the snapshot date below)
Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Strong" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-08-20), not the curated Frontier signal.
Key quality signals
| Revenue growth (YoY) | 25.8% |
|---|---|
| Gross margin | 58.7% |
| Gross profits / assets | 0.27 |
| Rule of 40 | 38 |
| Net margin | 12.2% |
| Cash runway (months) | — |
| PEG | 0.2 |
| Price / sales | 4.9 |
Quality checklist
- ✓ Revenue growth — 25.8% (pass ≥ 20%)
- ~ Gross profits / assets — 0.27 (pass ≥ 0.33)
- ~ Gross margin — 58.7% (pass ≥ 60%)
- ✓ Cash generation
- ✓ Share dilution — 0.4%
Fundamentals — snapshot as of 2026-08-20
| Stage | Established |
|---|---|
| Share issuance (YoY) | 0.4% · flat share count |
| Moat | — |
| TAM | — |
| P/E (trailing) | 24.3 |
| EPS (trailing) | $3.86 |
| Burn multiple | — |
| Gross-margin trend (pts) | -1.1 |
| Cash / assets | 0.32 |
| Net debt / EBITDA | 3.3 |
| Statements as of | Q2 FY2026 · filed 2026-08-04 |
Momentum context — a snapshot from 2026-08-20, not current
| Price at surface | $93.97 (as of 2026-08-20) |
|---|---|
| 52-week range | $60.105 – $156 |
| % off 52-wk high | -39.8% |
| RSI (14) | 71 |
| Relative volume | 0.7× |
Risk flags
← All broader-coverage names · Curated names → · Open the interactive screener →
Data as of 2026-08-20 (end-of-day). How grades are computed →